Can you say "superior" in Indian pharma promotional material?

Conditionally restricted. In Indian pharmaceutical promotion to doctors, 'superior' is not absolutely prohibited. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, it may be used only as a factual, fair comparison capable of substantiation (Clause 2.4). That comparison must not mislead by distortion, undue emphasis or omission (Clause 2.4). A competitor's brand name may be used in a comparison only with that company's prior consent (Clause 2.5).

In short

  • Status: conditionally restricted.
  • Governing instrument: Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Section 2 (Claims & Comparisons), Clauses 2.4, 2.5 and 2.6
  • UCPMP 2024 does not name this term.
  • First checked by two independent AI models against the live web. Citations re-checked on 6 October 2026. They were checked against the official text of the Code.

Which instrument governs this

Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Section 2 (Claims & Comparisons), Clauses 2.4, 2.5 and 2.6

UCPMP 2024 does not name this word. It is a comparative claim, so Clauses 2.4 to 2.6 govern it. The comparison must be factual, fair and capable of substantiation. A competitor's brand name may be used in a comparison only with that company's prior consent. Other companies and their products must not be disparaged.

What verification returned

In Indian pharmaceutical promotion to doctors, 'superior' is not absolutely prohibited. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, it may be used only as a factual, fair comparison capable of substantiation (Clause 2.4). That comparison must not mislead by distortion, undue emphasis or omission (Clause 2.4). A competitor's brand name may be used in a comparison only with that company's prior consent (Clause 2.5). Other companies and their products must not be disparaged (Clause 2.6). Cite specific comparative evidence, such as head-to-head trial results, rather than making an unqualified 'superior' claim.

How this was checked

Two independent AI models were asked the same question against the live web. They were Gemini 2.5 Pro with Google Search grounding, and OpenAI GPT-5 with web search. A third model then judged whether they agreed on the substance rather than the wording. Every source cited was fetched over HTTP to confirm it exists. A fetch confirms only that a source exists. It does not confirm that the source supports the statement. So on 6 October 2026 the citations on this page were re-checked. They were checked against the official text of the Code. They were corrected where they were wrong. Terms that did not reach agreement between the models are not published.

Sources checked

Frequently asked questions

Can you say "superior" in pharma promotion in India?

Conditionally restricted. In Indian pharmaceutical promotion to doctors, 'superior' is not absolutely prohibited. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, it may be used only as a factual, fair comparison capable of substantiation (Clause 2.4). That comparison must not mislead by distortion, undue emphasis or omission (Clause 2.4). A competitor's brand name may be used in a comparison only with that company's prior consent (Clause 2.5).

Which code governs the use of 'superior'?

Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Section 2 (Claims & Comparisons), Clauses 2.4, 2.5 and 2.6

How reliable is this answer?

It was first checked on 10 September 2026 by two independent AI models, Gemini 2.5 Pro and GPT-5. Both worked against the live web, and their answers were adjudicated for agreement. Every cited source was fetched to confirm it exists. A fetch confirms only that a source exists. So on 6 October 2026 the citations were re-checked. They were checked against the official text of the Code. They were corrected where they were wrong. Terms that did not reach agreement are not published. The Code can change, so check against the source before relying on it.

Check it before MLR does

Collateral Advisor flags this term in the pages you upload, for your team to review in context.

Free trial, no card needed. MarketingSense is a pre-MLR advisory assistant. Your medical, legal and regulatory team still makes the final call.

What this page is based on

  • Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Department of Pharmaceuticals
  • Drugs and Magic Remedies (Objectionable Advertisements) Act 1954
  • Drugs and Cosmetics Rules 1945, manufacturing licence conditions on advertising Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q))
  • Consumer Protection Act 2019 and the CCPA Guidelines 2022, for advertising to the public

General guidance for pharmaceutical marketing teams in India, reviewed 10 September 2026. Regulation and its interpretation change, and this page may not reflect the current position. It is not legal, regulatory or medical advice and it does not replace your own medical, legal and regulatory review. Please verify against the source text before relying on anything here. ImpactPlus Ventures LLP accepts no liability for decisions taken on the basis of this page.